EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and safety evaluation of Boswellia serrata and Curcuma longa extract combination in the management of chronic lower back pain: A randomised, double-blind, placebo-controlled clinical study

Anuradha Majumdar, Mungara Anjaneya Venkata Vara Prasad, Satish Reddy Gandavarapu, Kalakata Sudhir Kumar Reddy, Varun Sureja, Dharmeshkumar Kheni, Vishal Dubey

EXPLORE · 2025

DOI: 10.1016/j.explore.2024.103099 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EXPLORE, 2025. Verfasst von Anuradha Majumdar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, India. Hauptthemen laut MEDLINE: Boswellia, Plant Extracts, Low Back Pain, Curcuma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Chronic lower back pain (CLBP) is a major condition that leads to disability and reduced quality of life (QoL). This randomised, double-blind, placebo-controlled clinical study evaluated the efficacy and safety of a novel Boswellia serrata and Curcuma longa combination (CL20192) for the treatment of CLBP. MATERIAL AND METHODS: Participants with CLBP were randomised to receive either a 300 mg CL20192 capsule (n = 45) or placebo capsule (n = 45) once daily for 90 days. Efficacy was evaluated using the Descriptor Differential Scale and Oswestry Disability Index scores for pain, unpleasantness, and disability. Additionally, the 36-item short form questionnaire was used for QoL evaluation. Frequency of painkiller use, serum levels of inflammatory biomarkers (tumour necrosis factor-α, interleukin-6, and high-sensitivity C-reactive protein), and phytoconstituents (total boswellic acids and curcuminoids) were determined. Therapy satisfaction was assessed using the Physician and Patient Global Assessment Scales. RESULTS: All randomised participants completed the study. CL20192 supplementation significantly reduced Descriptor Differential Scale pain, unpleasantness, and Oswestry Disability Index scores compared with the placebo group (p < 0.001 for all parameters). Critical QoL scores greatly improved in the CL20192 group. Serum phytoconstituent levels were elevated in the CL20192-treated group. This group demonstrated a significant reduction in inflammatory biomarker levels (tumour necrosis factor-α, interleukin-6, and high-sensitivity C-reactive protein), confirming efficacy in abating CLBP compared with the placebo. Moreover, therapy satisfaction scores were significantly high in the CL20192-treated group, and intervention with CL20192 was well tolerated. CONCLUSION: Intervention with 300 mg CL20192 capsules, containing a novel combination of Boswellia serrata and Curcuma longa extracts, effectively alleviated pain, unpleasantness, and disability in patients with CLBP compared with the placebo. This outcome was consistent with a decrease in serum inflammatory markers and improved therapy assessment scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BoswelliaPlant ExtractsLow Back PainCurcumaChronic PainPhytotherapyHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultQuality of LifeAgedC-Reactive ProteinTreatment OutcomeTriterpenesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Boswellia serrataCL20192Curcuma longaInflammationLower back painQuality of life

Substanzen

Plant ExtractsC-Reactive ProteinTriterpenesTumor Necrosis Factor-alphaboswellic acid

Autor:innen und Institutionen

  • Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, India.
  • Vijaya Super Speciality Hospital, Raghava Cine Complex Road, SPSR Nellore, Andhra Pradesh, India.
  • Aster Prime Hospital, Maitrivanam, Satyam Theatre Road, Srinivasa Nagar, Ameerpet, Hyderabad, Telangana, India.
  • Landmark Hospital, Near JNTU Metro Station, Hyder Nagar, Main Road, Kukatpally, Hyderabad, Telangana, India.
  • Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, Gujarat, India. Electronic address: varun@sundyotanumandis.com.
  • Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, Gujarat, India.

Zitieren

APA

Majumdar, A., Prasad, M. A. V. V., Gandavarapu, S. R., Reddy, K. S. K., Sureja, V., Kheni, D., & Dubey, V. (2025). Efficacy and safety evaluation of Boswellia serrata and Curcuma longa extract combination in the management of chronic lower back pain: A randomised, double-blind, placebo-controlled clinical study. EXPLORE. https://doi.org/10.1016/j.explore.2024.103099

Vancouver

Majumdar A, Prasad MAVV, Gandavarapu SR, Reddy KSK, Sureja V, Kheni D, et al. Efficacy and safety evaluation of Boswellia serrata and Curcuma longa extract combination in the management of chronic lower back pain: A randomised, double-blind, placebo-controlled clinical study. EXPLORE. 2025. doi:10.1016/j.explore.2024.103099

BibTeX
@article{Majumdar2025,
  author = {Majumdar, Anuradha and Prasad, Mungara Anjaneya Venkata Vara and Gandavarapu, Satish Reddy and Reddy, Kalakata Sudhir Kumar and Sureja, Varun and Kheni, Dharmeshkumar and Dubey, Vishal},
  title = {Efficacy and safety evaluation of Boswellia serrata and Curcuma longa extract combination in the management of chronic lower back pain: A randomised, double-blind, placebo-controlled clinical study},
  journal = {EXPLORE},
  year = {2025},
  doi = {10.1016/j.explore.2024.103099}
}
Kostenlos starten →